Independent Pharmaceutical Research

China’s pharmaceutical industry, documented.

Fineline BioInsights publishes fully-sourced, English-language research on the world’s second-largest drug market — annual archives and disease-area reports written for executives, BD teams and investors who need to understand the market beyond the headlines.

Primary-source data Company publications PDF & hardcopy
Cover of the China Pharmaceutical Innovation Archive 2025

Latest Publication

CPIA 2025 · Annual Archive

The Catalogue

Our publications.

A growing library of research on China’s pharmaceutical industry. Each volume is built on primary regulatory sources, official approval data and verified transaction records.

Available now China Pharmaceutical Innovation Archive 2025 cover
Annual Archive · Industry

China Pharmaceutical Innovation Archive 2025

The definitive annual reference on China’s pharmaceutical innovation landscape — regulatory reforms, NRDL negotiations, license-out deals and payment reform, across 52 fully-sourced pages.

$599PDF or Hardcopy
View report →
Forthcoming Forthcoming cover preview: Report on Cardiovascular Health and Diseases in China 2025
Disease-area Report · Cardiovascular

Report on Cardiovascular Health and Diseases in China 2025

A dedicated deep-dive into China’s cardiovascular health and disease landscape — epidemiology, clinical practice and the market for cardiovascular therapeutics. In production.

In productionSubscribe for release updates
Get notified →

New disease-area and special reports are published as research completes. The catalogue grows with each edition — subscribe below to be notified of new releases.

Methodology

Research you can trace.

01

Primary regulatory sources

NMPA approval records, NHSA negotiation outcomes and official policy documents — read in the original, not through secondhand summaries.

02

Official approval data

Every approval, designation and reimbursement decision is drawn from the regulator’s own published data.

03

Verified transaction records

Licensing deals are checked against company disclosures and verified records. Where a figure is provisional, the report says so.

“We do not publish speculation.”Fineline BioInsights · Research Methodology

Editorial Team

The people behind the research.

Karia Olsen

Managing Editor

Pharmaceutical industry analyst with 15 years of experience. Master’s degree in Pharmacy from Fudan University; a decade at a multinational pharmaceutical consultancy.

Emily Zhang

Design Lead

Leona Zeng

Production Manager

Fineline BioInsights is the pharmaceutical research and publishing division of Fineline Information & Technology. All reports are company publications; copyright belongs to Fineline Information & Technology.

Research Areas

What we cover.

  1. 01

    Industry & Regulation

    NMPA approval trends, priority review, breakthrough designations, patent term extension and the reform history behind today’s market.

  2. 02

    Market Access & Payment

    NRDL negotiations, volume-based procurement and the pricing dynamics shaping patient access.

  3. 03

    Disease-area Reports

    Dedicated deep-dives into specific therapeutic areas — beginning with cardiovascular health and diseases.

  4. 04

    BD, Policy & Trade

    License-out transactions, NewCo structures, industrial policy and U.S.–China trade developments.

Insights

Research insights, forthcoming.

Short, sourced analysis of the developments that matter — drawn from our reports and the primary data behind them. New insights and report releases are announced to subscribers first.

No spam. Unsubscribe anytime. Report releases and research insights only. See our Privacy Policy.

The Catalogue

Understand the market beyond the headlines.